Clinical trial
A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary…
NCT00434642 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00434642 |
|---|---|
| Title | A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma |
| Official title | A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma |
| Acronym | OCEANS |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Carboplatin, Gemcitabine, Bevacizumab, Placebo |
| Enrollment | 484 |
| Start date | Apr 1, 2007 |
| Primary completion | Sep 1, 2010 |
| Completion | Jul 1, 2013 |
| First posted | Feb 13, 2007 |
| Last update posted | Aug 9, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: